contact profile privacysearch log in
HomeResources News BCG Shortage Addressed by Urologic Community


BCG Shortage Addressed by Urologic Community
Posted: February 20, 2019

This week, the Society of Urologic Oncology joined the American Urological Association, Bladder Cancer Advocacy Network, American Association of Clinical Urologists, LUGPA and Urology Care Foundation to express extreme concern about the shortage of TICE BCG and its effects on the care of patients with bladder cancer. Although Merck, the sole supplier of BCG to the United States, is exploring options to increase their production of TICE BCG, they expect this global supply constraint to continue throughout 2019. Efforts to engage the U.S. Food and Drug Administration to approve additional strains and supplies of BCG are ongoing and all these organizations continue to communicate with Merck for up-to-date information on this issue.

Until the shortage has been resolved, the following strategies may help maximize the care for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), subject, as always, to physician judgment in individual cases:

  1. BCG should not be used for patients with low-risk disease.
  2. Intravesical chemotherapy should be used as the first-line option for patients with intermediate-risk NMIBC. Patients with recurrent/multifocal low-grade Ta lesions who require intravesical therapy should receive intravesical chemotherapy such as mitomycin, gemcitabine, epirubicin or docetaxel instead of BCG.
  3. If BCG would be administered as second-line therapy for patients with intermediate-risk NMIBC, an alternative intravesical chemotherapy should be used rather than BCG in the setting of this BCG shortage.
  4. For patients with high-risk NMIBC, high-grade T1 and CIS patients receiving induction therapy should be prioritized for use of full-strength BCG. If not available, these patients and other high-risk patients should be given a reduced 1/2- 1/3 dose, if feasible.
  5. If supply exists for maintenance therapy for patients with NMIBC, every attempt should be made to use 1/3 dose BCG and limit dose to one year.
  6. In the event of BCG supply shortage, maintenance therapy should not be given and BCG-naïve patients with high-risk disease should be prioritized for induction BCG.
  7. If BCG is not available, a preferable alternative to BCG is mitomycin (induction and monthly maintenance up to one year). Other options such as gemcitabine, epirubicin, docetaxel, valrubicin or sequential gemcitabine/docetaxel or gemcitabine/mitomycin may also be considered with an induction and possible maintenance regimen.
  8. Patients with high-risk features (i.e., high-grade T1 with additional risk factors such as concomitant carcinoma in situ, lymphovascular invasion, prostatic urethral involvement, or variant histology) who are not willing to take any potential oncologic risks with alternative intravesical agents should be offered initial radical cystectomy if they are surgical candidates.
Additional Notes

If 1/2 to 1/3 dose BCG is used, every attempt should be made to treat multiple patients on the same day, while being consistent with product labeling, to avoid drug wastage. It is recommended that practitioners talk with their pharmacy to ensure that if split dosing is used, it is done with appropriate safety precautions.

As always, it is important that these decisions be made after an informed discussion with the individual patient regarding their treatment options in the context of the ongoing BCG shortage.

Note: It is recognized that there are legitimate concerns around split-vial dosing of BCG. It is unknown at this time whether it is acceptable to bill for more than one patient per vial of BCG. The AUA has been in contact with the Centers for Medicare & Medicaid Services (CMS) and is awaiting billing guidance for practices implementing split-vial dosing, if allowed in the Medicare program. At this time, the AUA suggests confirmation with any insurance company prior to splitting vials on their billing guidance.

Every effort should be made to enroll patients in clinical trials to offer an appropriate alternative management strategy where this is feasible.

Review the official AUA/SUO Risk Stratification Table for NMIBC.

We will continue to update you as we receive additional information.